<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d556" origId="Lovastatin"><sentence id="DrugDDI.d556.s0" origId="s0" text="CYP3A4 Interactions"><entity id="DrugDDI.d556.s0.e0" origId="s0.p0" charOffset="0-6" type="drug" text="CYP3A4"/></sentence><sentence id="DrugDDI.d556.s1" origId="s1" text="Lovastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity;"><entity id="DrugDDI.d556.s1.e0" origId="s1.p1" charOffset="0-10" type="drug" text="Lovastatin"/><entity id="DrugDDI.d556.s1.e1" origId="s1.p4" charOffset="29-35" type="drug" text="CYP3A4"/><entity id="DrugDDI.d556.s1.e2" origId="s1.p7" charOffset="47-53" type="drug" text="CYP3A4"/><pair id="DrugDDI.d556.s1.p0" e1="DrugDDI.d556.s1.e0" e2="DrugDDI.d556.s1.e1" interaction="true"/><pair id="DrugDDI.d556.s1.p1" e1="DrugDDI.d556.s1.e0" e2="DrugDDI.d556.s1.e2" interaction="false"/><pair id="DrugDDI.d556.s1.p2" e1="DrugDDI.d556.s1.e1" e2="DrugDDI.d556.s1.e2" interaction="false"/></sentence><sentence id="DrugDDI.d556.s2" origId="s2" text="therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4."><entity id="DrugDDI.d556.s2.e0" origId="s2.p16" charOffset="74-79" type="drug" text="drugs"/><entity id="DrugDDI.d556.s2.e1" origId="s2.p18" charOffset="95-101" type="drug" text="CYP3A4"/><pair id="DrugDDI.d556.s2.p0" e1="DrugDDI.d556.s2.e0" e2="DrugDDI.d556.s2.e1" interaction="false"/></sentence><sentence id="DrugDDI.d556.s3" origId="s3" text="Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of lovastatin."><entity id="DrugDDI.d556.s3.e0" origId="s3.p20" charOffset="21-27" type="drug" text="CYP3A4"/><entity id="DrugDDI.d556.s3.e1" origId="s3.p28" charOffset="97-107" type="drug" text="lovastatin"/><pair id="DrugDDI.d556.s3.p0" e1="DrugDDI.d556.s3.e0" e2="DrugDDI.d556.s3.e1" interaction="true"/></sentence><sentence id="DrugDDI.d556.s4" origId="s4" text="Pharmacokinetics."/><sentence id="DrugDDI.d556.s5" origId="s5" text="Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)"><entity id="DrugDDI.d556.s5.e0" origId="s5.p30" charOffset="0-12" type="drug" text="Itraconazole"/></sentence><sentence id="DrugDDI.d556.s6" origId="s6" text="Interactions with lipid-lowering drugs that can cause myopathy when given alone."><entity id="DrugDDI.d556.s6.e0" origId="s6.p36" charOffset="18-38" type="drug" text="lipid-lowering drugs"/></sentence><sentence id="DrugDDI.d556.s7" origId="s7" text="The risk of myopathy is also increased by the following lipid-lowering drugs that are not potent CYP3A4 inhibitors, but which can cause myopathy when given alone."><entity id="DrugDDI.d556.s7.e0" origId="s7.p48" charOffset="56-76" type="drug" text="lipid-lowering drugs"/><entity id="DrugDDI.d556.s7.e1" origId="s7.p51" charOffset="97-103" type="drug" text="CYP3A4"/><pair id="DrugDDI.d556.s7.p0" e1="DrugDDI.d556.s7.e0" e2="DrugDDI.d556.s7.e1" interaction="false"/></sentence><sentence id="DrugDDI.d556.s8" origId="s8" text="See WARNINGS, Myopathy/Rhabdomyolysis."/><sentence id="DrugDDI.d556.s9" origId="s9" text="Gemfibrozil Other fibrates Niacin (nicotinic acid) (=1 g/day)"><entity id="DrugDDI.d556.s9.e0" origId="s9.p63" charOffset="0-12" type="drug" text="Gemfibrozil"/><entity id="DrugDDI.d556.s9.e1" origId="s9.p65" charOffset="35-49" type="drug" text="nicotinic acid"/><pair id="DrugDDI.d556.s9.p0" e1="DrugDDI.d556.s9.e0" e2="DrugDDI.d556.s9.e1" interaction="false"/></sentence><sentence id="DrugDDI.d556.s10" origId="s10" text="Other drug interactions"/><sentence id="DrugDDI.d556.s11" origId="s11" text="Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis)."><entity id="DrugDDI.d556.s11.e0" origId="s11.p72" charOffset="0-7" type="drug" text="Danazol"/><entity id="DrugDDI.d556.s11.e1" origId="s11.p80" charOffset="91-98" type="drug" text="danazol"/><entity id="DrugDDI.d556.s11.e2" origId="s11.p82" charOffset="133-143" type="drug" text="lovastatin"/><pair id="DrugDDI.d556.s11.p0" e1="DrugDDI.d556.s11.e0" e2="DrugDDI.d556.s11.e1" interaction="false"/><pair id="DrugDDI.d556.s11.p1" e1="DrugDDI.d556.s11.e0" e2="DrugDDI.d556.s11.e2" interaction="false"/><pair id="DrugDDI.d556.s11.p2" e1="DrugDDI.d556.s11.e1" e2="DrugDDI.d556.s11.e2" interaction="true"/></sentence><sentence id="DrugDDI.d556.s12" origId="s12" text="Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis)."><entity id="DrugDDI.d556.s12.e0" origId="s12.p89" charOffset="0-10" type="drug" text="Amiodarone"/><entity id="DrugDDI.d556.s12.e1" origId="s12.p91" charOffset="14-23" type="drug" text="Verapamil"/><entity id="DrugDDI.d556.s12.e2" origId="s12.p100" charOffset="86-96" type="drug" text="amiodarone"/><entity id="DrugDDI.d556.s12.e3" origId="s12.p102" charOffset="100-109" type="drug" text="verapamil"/><entity id="DrugDDI.d556.s12.e4" origId="s12.p107" charOffset="169-196" type="drug" text="hmg-coa reductase inhibitor"/><pair id="DrugDDI.d556.s12.p0" e1="DrugDDI.d556.s12.e0" e2="DrugDDI.d556.s12.e1" interaction="false"/><pair id="DrugDDI.d556.s12.p1" e1="DrugDDI.d556.s12.e0" e2="DrugDDI.d556.s12.e2" interaction="false"/><pair id="DrugDDI.d556.s12.p2" e1="DrugDDI.d556.s12.e0" e2="DrugDDI.d556.s12.e3" interaction="false"/><pair id="DrugDDI.d556.s12.p3" e1="DrugDDI.d556.s12.e0" e2="DrugDDI.d556.s12.e4" interaction="false"/><pair id="DrugDDI.d556.s12.p4" e1="DrugDDI.d556.s12.e1" e2="DrugDDI.d556.s12.e2" interaction="false"/><pair id="DrugDDI.d556.s12.p5" e1="DrugDDI.d556.s12.e1" e2="DrugDDI.d556.s12.e3" interaction="false"/><pair id="DrugDDI.d556.s12.p6" e1="DrugDDI.d556.s12.e1" e2="DrugDDI.d556.s12.e4" interaction="false"/><pair id="DrugDDI.d556.s12.p7" e1="DrugDDI.d556.s12.e2" e2="DrugDDI.d556.s12.e3" interaction="false"/><pair id="DrugDDI.d556.s12.p8" e1="DrugDDI.d556.s12.e2" e2="DrugDDI.d556.s12.e4" interaction="true"/><pair id="DrugDDI.d556.s12.p9" e1="DrugDDI.d556.s12.e3" e2="DrugDDI.d556.s12.e4" interaction="false"/></sentence><sentence id="DrugDDI.d556.s13" origId="s13" text="Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected."><entity id="DrugDDI.d556.s13.e0" origId="s13.p114" charOffset="0-22" type="drug" text="Coumarin Anticoagulant"/><entity id="DrugDDI.d556.s13.e1" origId="s13.p117" charOffset="60-70" type="drug" text="lovastatin"/><entity id="DrugDDI.d556.s13.e2" origId="s13.p120" charOffset="91-99" type="drug" text="warfarin"/><pair id="DrugDDI.d556.s13.p0" e1="DrugDDI.d556.s13.e0" e2="DrugDDI.d556.s13.e1" interaction="false"/><pair id="DrugDDI.d556.s13.p1" e1="DrugDDI.d556.s13.e0" e2="DrugDDI.d556.s13.e2" interaction="false"/><pair id="DrugDDI.d556.s13.p2" e1="DrugDDI.d556.s13.e1" e2="DrugDDI.d556.s13.e2" interaction="false"/></sentence><sentence id="DrugDDI.d556.s14" origId="s14" text="However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin."><entity id="DrugDDI.d556.s14.e0" origId="s14.p126" charOffset="17-44" type="drug" text="hmg-coa reductase inhibitor"/><entity id="DrugDDI.d556.s14.e1" origId="s14.p139" charOffset="168-176" type="drug" text="warfarin"/><pair id="DrugDDI.d556.s14.p0" e1="DrugDDI.d556.s14.e0" e2="DrugDDI.d556.s14.e1" interaction="true"/></sentence><sentence id="DrugDDI.d556.s15" origId="s15" text="Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin."><entity id="DrugDDI.d556.s15.e0" origId="s15.p149" charOffset="93-115" type="drug" text="coumarin anticoagulant"/><entity id="DrugDDI.d556.s15.e1" origId="s15.p150" charOffset="136-146" type="drug" text="lovastatin"/><pair id="DrugDDI.d556.s15.p0" e1="DrugDDI.d556.s15.e0" e2="DrugDDI.d556.s15.e1" interaction="true"/></sentence><sentence id="DrugDDI.d556.s16" origId="s16" text="It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs."><entity id="DrugDDI.d556.s16.e0" origId="s16.p157" charOffset="42-56" type="drug" text="anticoagulants"/><entity id="DrugDDI.d556.s16.e1" origId="s16.p161" charOffset="105-115" type="drug" text="lovastatin"/><pair id="DrugDDI.d556.s16.p0" e1="DrugDDI.d556.s16.e0" e2="DrugDDI.d556.s16.e1" interaction="false"/></sentence><sentence id="DrugDDI.d556.s17" origId="s17" text="Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants."><entity id="DrugDDI.d556.s17.e0" origId="s17.p182" charOffset="140-162" type="drug" text="coumarin anticoagulant"/></sentence><sentence id="DrugDDI.d556.s18" origId="s18" text="If the dose of lovastatin is changed, the same procedure should be repeated."><entity id="DrugDDI.d556.s18.e0" origId="s18.p184" charOffset="15-25" type="drug" text="lovastatin"/></sentence><sentence id="DrugDDI.d556.s19" origId="s19" text="Lovastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants."><entity id="DrugDDI.d556.s19.e0" origId="s19.p192" charOffset="0-10" type="drug" text="Lovastatin"/><entity id="DrugDDI.d556.s19.e1" origId="s19.p202" charOffset="116-130" type="drug" text="anticoagulants"/><pair id="DrugDDI.d556.s19.p0" e1="DrugDDI.d556.s19.e0" e2="DrugDDI.d556.s19.e1" interaction="false"/></sentence><sentence id="DrugDDI.d556.s20" origId="s20" text="Propranolol: In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and propranolol."><entity id="DrugDDI.d556.s20.e0" origId="s20.p203" charOffset="0-11" type="drug" text="Propranolol"/><entity id="DrugDDI.d556.s20.e1" origId="s20.p213" charOffset="169-179" type="drug" text="lovastatin"/><entity id="DrugDDI.d556.s20.e2" origId="s20.p215" charOffset="184-195" type="drug" text="propranolol"/><pair id="DrugDDI.d556.s20.p0" e1="DrugDDI.d556.s20.e0" e2="DrugDDI.d556.s20.e1" interaction="false"/><pair id="DrugDDI.d556.s20.p1" e1="DrugDDI.d556.s20.e0" e2="DrugDDI.d556.s20.e2" interaction="false"/><pair id="DrugDDI.d556.s20.p2" e1="DrugDDI.d556.s20.e1" e2="DrugDDI.d556.s20.e2" interaction="false"/></sentence><sentence id="DrugDDI.d556.s21" origId="s21" text="Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations."><entity id="DrugDDI.d556.s21.e0" origId="s21.p216" charOffset="0-7" type="drug" text="Digoxin"/><entity id="DrugDDI.d556.s21.e1" origId="s21.p221" charOffset="78-88" type="drug" text="lovastatin"/><entity id="DrugDDI.d556.s21.e2" origId="s21.p223" charOffset="93-100" type="drug" text="digoxin"/><entity id="DrugDDI.d556.s21.e3" origId="s21.p226" charOffset="126-133" type="drug" text="digoxin"/><pair id="DrugDDI.d556.s21.p0" e1="DrugDDI.d556.s21.e0" e2="DrugDDI.d556.s21.e1" interaction="false"/><pair id="DrugDDI.d556.s21.p1" e1="DrugDDI.d556.s21.e0" e2="DrugDDI.d556.s21.e2" interaction="false"/><pair id="DrugDDI.d556.s21.p2" e1="DrugDDI.d556.s21.e0" e2="DrugDDI.d556.s21.e3" interaction="false"/><pair id="DrugDDI.d556.s21.p3" e1="DrugDDI.d556.s21.e1" e2="DrugDDI.d556.s21.e2" interaction="false"/><pair id="DrugDDI.d556.s21.p4" e1="DrugDDI.d556.s21.e1" e2="DrugDDI.d556.s21.e3" interaction="false"/><pair id="DrugDDI.d556.s21.p5" e1="DrugDDI.d556.s21.e2" e2="DrugDDI.d556.s21.e3" interaction="false"/></sentence><sentence id="DrugDDI.d556.s22" origId="s22" text="Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide"><entity id="DrugDDI.d556.s22.e0" origId="s22.p227" charOffset="5-24" type="drug" text="Hypoglycemic Agents"/><entity id="DrugDDI.d556.s22.e1" origId="s22.p230" charOffset="56-63" type="drug" text="MEVACOR"/><entity id="DrugDDI.d556.s22.e2" origId="s22.p235" charOffset="163-172" type="drug" text="glipizide"/><entity id="DrugDDI.d556.s22.e3" origId="s22.p237" charOffset="181-195" type="drug" text="chlorpropamide"/><pair id="DrugDDI.d556.s22.p0" e1="DrugDDI.d556.s22.e0" e2="DrugDDI.d556.s22.e1" interaction="false"/><pair id="DrugDDI.d556.s22.p1" e1="DrugDDI.d556.s22.e0" e2="DrugDDI.d556.s22.e2" interaction="false"/><pair id="DrugDDI.d556.s22.p2" e1="DrugDDI.d556.s22.e0" e2="DrugDDI.d556.s22.e3" interaction="false"/><pair id="DrugDDI.d556.s22.p3" e1="DrugDDI.d556.s22.e1" e2="DrugDDI.d556.s22.e2" interaction="false"/><pair id="DrugDDI.d556.s22.p4" e1="DrugDDI.d556.s22.e1" e2="DrugDDI.d556.s22.e3" interaction="false"/><pair id="DrugDDI.d556.s22.p5" e1="DrugDDI.d556.s22.e2" e2="DrugDDI.d556.s22.e3" interaction="false"/></sentence></document>